Page 2 of Dr Reddy's Laboratories

The Hyderabad-based drug major had reported a profit of Rs 1,379 crore for the October-December period of last fiscal. Revenue…

In 2023, Dr. Reddy’s entered into a licensing and commercialization agreement with Shanghai Junshi Biosciences for toripalimab.

Nasopharyngeal carcinoma (NPC) is a rare, aggressive form of head and neck cancer that originates in the nasopharynx, the upper…

Additionally, the fine was imposed due to an error in the date of the invoice and also in the name…

Around 12 percent of the population in India suffers from symptoms of constipation, heavily impacting their quality of life, the…

According to the company’s press statement, it is India’s first trial for a novel autologous BCMA directed CAR-T cell therapy…

Additionally, Lenacapavir is currently under investigation for the prevention of HIV (PrEP) which is yet to be approved globally.